Fusion Antibodies Shares Rise on US Cancer Institute Collaboration
28 Noviembre 2023 - 7:23AM
Noticias Dow Jones
By Ian Walker
Fusion Antibodies shares rose 58% after the company said that it
has signed a collaboration agreement with the U.S. National Cancer
Institute toward the discovery of potential therapeutic
antibodies.
Shares at 1242 GMT on Tuesday were up 2.0 pence at 5.45 pence,
marking their best one-day percentage performance since September
2020.
Under the deal the U.K. biotechnology company will provide the
NCI with access to its OptiMAL technology against an agreed number
of cancer targets for up to two years. The parties will work
together to ensure successful validation of the technology and
jointly publish any results.
NCI, part of the U.S. National Institutes of Health, is the U.S.
federal government's main agency for cancer research and
training.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
November 28, 2023 08:08 ET (13:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De May 2023 a May 2024
